Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dabigatran etexilate Clear all
Completed No phase listed Observational

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

NCT04394234
View directory record Official record
Conditions
Uterine Hemorrhage
Interventions
Direct oral anticoagulant (DOACs), Warfarin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
961,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

NCT03539055
View directory record Official record
Conditions
Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis, Watchman LAA Closure Device
Interventions
Dabigatran Etexilate Oral Capsule
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 9, 2026, 1:27 PM EDT
Not listed No phase listed Observational

The DARE Warfarin CER Study

NCT03271450
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
416,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Results available

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

NCT02348723
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Warfarin, Dabigatran Etexilate 150mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Little Rock, Arkansas • Fremont, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 9, 2026, 1:27 PM EDT
Terminated Not applicable Interventional Results available

Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)

NCT03465735
View directory record Official record
Conditions
Acute DVT of Lower Extremity
Interventions
Vascular Boot, Standard of Care
Combination Product · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

NCT00291330
View directory record Official record
Conditions
Thromboembolism
Interventions
dabigatran etexilate 150 mg, warfarin (INR 2-3)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
23
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Not applicable Interventional

Use of Electronic Personal Health Records to Improve Medication Adherence

NCT03018197
View directory record Official record
Conditions
Atrial Fibrillation, Medication Adherence
Interventions
Medication Education
Other
Lead sponsor
Parkview Health
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Results available

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

NCT01493557
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
pantoprazole, Pradaxa (dabigatran etexilate), Pradaxa, within 30 minutes after a meal
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 9, 2026, 1:27 PM EDT
Completed No phase listed Observational Results available

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

NCT03026556
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
42,534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

NCT04782076
View directory record Official record
Conditions
Healthy
Interventions
Dabigatran, Selpercatinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 9, 2026, 1:27 PM EDT
Completed No phase listed Observational Results available

Anticoagulant Utilization Pattern

NCT01847560
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
333,664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

NCT04498741
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 9, 2026, 1:27 PM EDT
Recruiting No phase listed Observational

Registry of Patients Prescribed Anticoagulation

NCT03504007
View directory record Official record
Conditions
Acute Deep Vein Thrombosis, Acute Pulmonary Embolism
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 9, 2026, 1:27 PM EDT
Withdrawn Not applicable Interventional

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

NCT04684212
View directory record Official record
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 9, 2026, 1:27 PM EDT
Withdrawn No phase listed Observational

Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation

NCT01607359
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 9, 2026, 1:27 PM EDT
Withdrawn Phase 2 Interventional

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

NCT01773174
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Year to 2 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Sacramento, California • Louisville, Kentucky • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

NCT04809818
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
LT3001 drug product, Placebo, Aspirin, Clopidogrel, Apixaban, Dabigatran
Drug
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 9, 2026, 1:27 PM EDT
Terminated Phase 4 Interventional Results available

Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

NCT01546883
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran etexilate (Pradaxa)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

NCT01896622
View directory record Official record
Conditions
HIV
Interventions
Ritonavir, Cobicistat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

NCT02568397
View directory record Official record
Conditions
Healthy
Interventions
Lanabecestat, Dabigatran etexilate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

NCT02239120
View directory record Official record
Conditions
Stroke, Secondary Prevention
Interventions
optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 150 Years
Enrollment
5,390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
110
States / cities
Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 9, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108
View directory record Official record
Conditions
Drug Interaction
Interventions
Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 9, 2026, 1:27 PM EDT
Recruiting Early Phase 1 Interventional

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

NCT06615596
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
Behavioral · Drug · Procedure
Lead sponsor
China National Center for Cardiovascular Diseases
Government
Eligibility
18 Years and older
Enrollment
3,160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 9, 2026, 1:27 PM EDT